Avutometinib

Definition

An orally bioavailable inhibitor of the serine/threonine protein kinases Raf and mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK), with potential antineoplastic activity. Upon oral administration, avutometinib specifically targets, binds to and inhibits the kinase activities of Raf and MEK, resulting in the inhibition of Raf/MEK-mediated signal transduction pathways. This results in the inhibition of Raf/MEK-dependent tumor cell proliferation and survival. The RAS/RAF/MEK/extracellular signal-regulated kinase (ERK) signaling pathway is often dysregulated in human cancers and plays a key role in tumor cell proliferation, differentiation and survival.

Also known as AVUTOMETINIB, CH-5126766, CH5126766, CKI-27, R-7304, Raf/MEK Inhibitor VS-6766, RG 7304, RG-7304, RG7304, RO5126766, VS 6766, VS-6766, VS6766 — per NCIT

Also identified as

• NCIT NCIT:C80060 per NCIT
• UNII D0D4252V97 per RXNORM

Indications